Compare RNST & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | PCVX |
|---|---|---|
| Founded | 1904 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 6.0B |
| IPO Year | N/A | 2020 |
| Metric | RNST | PCVX |
|---|---|---|
| Price | $36.34 | $46.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $43.17 | ★ $101.67 |
| AVG Volume (30 Days) | 484.8K | ★ 1.5M |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $775,309,000.00 | N/A |
| Revenue This Year | $43.37 | N/A |
| Revenue Next Year | $13.13 | N/A |
| P/E Ratio | $19.79 | ★ N/A |
| Revenue Growth | ★ 13.04 | N/A |
| 52 Week Low | $26.97 | $27.66 |
| 52 Week High | $40.40 | $94.60 |
| Indicator | RNST | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 51.97 |
| Support Level | $35.16 | $43.78 |
| Resistance Level | $36.18 | $48.11 |
| Average True Range (ATR) | 0.80 | 1.99 |
| MACD | 0.25 | -0.49 |
| Stochastic Oscillator | 96.11 | 42.99 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.